This is the text extract for Consultation: Various pharmaceuticals Section B, browse documents here.

23 May 2007 To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

Proposal to amend restrictions for various pharmaceuticals in Section B of the Pharmaceutical Schedule

PHARMAC is proposing to amend the restrictions currently applying to amantadine hydrochloride, apomorphine hydrochloride, clobazam tab, entacapone and selegiline hydrochloride tab 5 mg in Section B of the Pharmaceutical, with effect from 1 August 2007. We are now seeking feedback on this proposal. Proposed amendments are as follows (proposed deletions in strikethrough): Amantadine hydrochloride

AMANTADINE HYDROCHLORIDE – Retail pharmacy-Specialist Cap 100 mg

Apomorphine hydrochloride

APOMORPHINE HYDROCHLORIDE – Hospital pharmacy [HP3]-Specialist Inj 10 mg per ml, 1 ml

Clobazam

CLOBAZAM – Retail pharmacy-Specialist Tab 10 mg

Entacapone

ENTACAPONE – Retail pharmacy-Specialist Tab 200 mg

Selegiline hydrochloride

SELEGILINE HYDROCHLORIDE – Retail pharmacy-Specialist Tab 5 mg

If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC by 5:00 pm, 8 June 2007. All comments submitted by this date will be considered. Yours sincerely

Geraldine MacGibbon Therapeutic Group Manager

A127944 - T07-065